Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis

Laboratory Investigation

Volumn 91, Issue 5, 2011, Pages 719-731

  Teramachi, Junpei ^a   Kukita, Akiko ^b   Li, Yin Ji ^a   Ushijima, Yuki ^a   Ohkuma, Hiroshi ^a   Wada, Naohisa ^a   Watanabe, Toshiyuki ^a   Nakamura, Seiji ^a   Kukita, Toshio ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

adenosine; adenosine receptor A2b; adjuvant arthritis; bone destruction; HPLC; methotrexate; osteoclast; osteoprotegerin

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADJUVANT; CAFFEINE; METHOTREXATE; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL CELL; ARTICLE; BONE DESTRUCTION; DRUG MECHANISM; DRUG RESISTANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS;

EID: 79955548681     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.9     Document Type: Article

References (40)

1. Shimizu S, Shiozawa S, Shiozawa K, et al. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 1985;28:25-31. (Pubitemid 15193018)
2. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292-304. (Pubitemid 46480961)
3. Singer FR. Paget disease: when to treat and when not to treat. Nat Rev Rheumatol 2009;5:483-489.
4. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787-793.
5. Geiser CF, Bishop Y, Jaffe N III, et al. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 1975;45:189-195.
6. Thompson PA, Murry DJ, Rosner GL, et al. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2007;59:847-853. (Pubitemid 46440608)
7. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-822. (Pubitemid 15104774)
8. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997;24:1489-1494. (Pubitemid 27320687)
9. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arth Rheumat 2000;43:2316-2327.
10. Barbieri M, Wong JB, Drummond M. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics 2005;23:607-618. (Pubitemid 40994128)
11. Romas E, Gillespie MT. Inflammation-induced bone loss: can it be prevented? Rheum Dis Clin North Am 2006;32:759-773. (Pubitemid 46590093)
12. OBrien CA. Control of RANKL gene expression. Bone 2010;46:911-919.
13. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342. (Pubitemid 40852708)
14. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20: 345-357. (Pubitemid 30649812)
15. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008;1143:123-150.
16. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-264. (Pubitemid 43336037)
17. Kukita A, Kukita T, Hata K, et al. Heat-treated osteoblastic cell (ROS17/2.8)-conditioned medium induces the formation of osteoclast-like cells. Bone Miner 1993;23:113-127.
18. Kukita A, Kukita T, Shin JH, et al. Induction of mononuclear precursor cells with osteoclastic phenotypes in a rat bone marrow culture system depleted of stromal cells. Biochem Biophys Res Commun 1993;196:1383-1389. (Pubitemid 23347603)
19. Takahashi N, Akatsu T, Udagawa N, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988;123:2600-2602.
20. Kuratani T, Nagata K, Kukita T, et al. Induction of abundant osteoclastlike multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol Histopathol 1998;13:751-759. (Pubitemid 28329179)
21. Nakamura T, Kukita T, Shobuike T, et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 2005;175:5809-5816. (Pubitemid 41508065)
22. Sullivan GW, Rieger JM, Scheld WM, et al. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2- propynylcyclohexyl adenosine A(2A) receptor agonists. Br J Pharmacol 2001;132:1017-1026. (Pubitemid 32238907)
23. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004;25:33-39. (Pubitemid 38032805)
24. Martin C, Leone M, Viviand X, et al. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med 2000;28:3198-3202.
25. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994;76:5-13. (Pubitemid 24048220)
26. Kara FM, Chitu V, Sloane J, et al. Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function. FASEB J 2010;24:2325-2333.
27. Kara FM, Doty SB, Boskey A, et al. Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. Arthritis Rheum 2010;62:534-541.
28. Montesinos M, Desai A, Delano D, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by metotrexate and its analogue MX-68. Arthritis Rheum 2003;48:240-247. (Pubitemid 36091669)
29. Montesinos M, Yap J, Desai A, et al. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists teophillin and caffein: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000;43:659-663.
30. Baharav E, Bar-Tehuda S, Madi L, et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis model. J Rheumatol 2005;32:469-476. (Pubitemid 40381417)
31. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999;5:621-627. (Pubitemid 29131973)
32. Serra M, Reverter-Branchat G, Maurici D, et al. Analysis of dihydrofolatereductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 2004;15:151-160. (Pubitemid 38145532)
33. Yang R, Li WW, Hoang BH, et al. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. BMC Cancer 2008;8:124.
34. Stark M, Wichman C, Avivi I, et al. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009;113:4362-4369.
35. Lee CK, Lee EY, Chung SM, et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 2004;50:3831-3843.
36. Suematsu A, Tajiri Y, Nakashima T, et al. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol 2007;17:17-23. (Pubitemid 46758765)
37. Evans BA, Elford C, Pexa A, et al. Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. J Bone Miner Res 2006;21:228-236. (Pubitemid 43265288)
38. Hazama R, Qu X, Yokoyama K, et al. ATP-induced osteoclast function: the formation of sealing-zone like structure and the secretion of lytic granules via microtubule-deacetylation under the control of Syk. Genes Cells 2009;14:871-884.
39. Armstrong S, Pereverzev A, Dixon SJ, et al. Activation of P2X7 receptors causes isoform-specific translocation of protein kinase C in osteoclasts. J Cell Sci 2009;122(Part 1):136-144.
40. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-172. (Pubitemid 41043882)